ArticleIn vitro cellular & developmental biology. Animal2025
Compatibility of Calycosin-Tanshinone IIA improves Ang II-induced renal artery endothelial cell dysfunction through lncRNA-mRNA co-expression network.
Article in In vitro cellular & developmental biology. Animal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic target exploration of Shugan Jianpi formula in liver fibrosis: an integrated lncRNA-mRNA co-expression network analysis.Molecular genetics and genomics : MGG · 2026Article
- Review
- Calycosin accelerates wound healing in diabetic rats by alleviating oxidative stress and promoting angiogenesis.Histology and histopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed to investigate the effect of the compatibility of Calycosin and Tanshinone IIA on dysfunction of rat renal artery endothelial cells (RRAECs) induced by angiotensin II (Ang II) and to elucidate the underlying molecular mechanisms. We utilized cell culture to optimize Calycosin and Tanshinone IIA concentrations and assessed autophagy, apoptosis, ATP levels, and cell migration using MDC staining, Annexin V-FITC/PI staining, ATP assay, and Transwell assays, respectively. RNA-seq identified differentially expressed lncRNAs and mRNAs, which were validated by qRT-PCR. The compatibility of Calycosin and Tanshinone IIA significantly enhanced the proliferative capacity of Ang II-induced RRAECs, increased autophagosome formation, reduced cell apoptosis, elevated ATP production, and enhanced cell migration ability. RNA sequencing analysis revealed 146 differentially expressed lncRNAs and 43 differentially expressed mRNAs, and co-expression network analysis identified interactions between 28 lncRNAs and 7 mRNAs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses indicated that these differentially expressed mRNAs were primarily involved in the regulation of ATPase activity and metabolic processes related to serine family amino acids, triglycerides, arachidonic acid, etc., as well as the MAPK signaling pathway. The compatibility of Calycosin and Tanshinone IIA improved Ang II-induced dysfunction in RRAECs by modulating the lncRNA-mRNA co-expression network, providing new molecular targets and therapeutic strategies for the prevention and treatment of hypertensive renal damage.
Indexed as
Identifiers
39939539What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.